Edwards Lifesciences ( NYSE:EW ) First Quarter 2024 Results Key Financial Results Revenue: US$1.60b (up 9.5% from 1Q...
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.